I really like that PYC have provided guidance as to what the SAD study for PKD is budgeted to cost, ($10M). In a way PYC seems quietly confident that they will probably garner some early and truly valuable data covering safety and efficacy later in 2025, from progressive and validated test results.
I think that data could likely serve us really well when it comes to negotiating a BD, to possibly support later stage trials for PKD, which will surely be way more expensive than the SAD study. Such a trajectory would see us moving forward from a position of strength, especially with robust safety and efficacy data in our back pocket.
Knowing the budget for PKD, (SAD study), could also work to the favour of our share price as shareholders and potential shareholders would have a clearer picture of our cash runway, overlaid with likely clinical advancements of not just one but THREE indications that have now commenced human trials.
PYC Price at posting:
$1.30 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)